Drakeman resigns from Medarex

Six months after MEDX announced an informal SEC investigation related to backdated stock options, Donald Drakeman resigned on Monday as president, CEO and a director of the antibody play. Drakeman was

Read the full 313 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE